CERSI-PGx advances pharmacogenomics through five dedicated work packages (WPs), each focused on a core area of research, education, regulatory guidance, and patient involvement. Together, these WPs ensure a coordinated approach to integrating pharmacogenomics into UK healthcare and regulatory pathways.
- WP1 – Developing UK-Based Guidelines
- WP2 – Pathway for Industry Pharmacogenomic Testing
- WP3 – Education and Training
- WP4 – Health Economics of PGx
- WP5 – Patient and Public Engagement
WP1 – Developing UK-Based Guidelines
Leads: Professor Sir Munir Pirmohamed, Dr Cinzia Dello Russo
Purpose: Generate standard templates for UK pharmacogenomic guidelines and publish them for wide dissemination.
WP2 – Pathway for Industry Pharmacogenomic Testing
Leads: Mark Wigglesworth, Jackie O’Brien
Purpose: Define industry and regulatory issues, conduct gap analyses, streamline commercial assay accreditation, and design a regulatory portal.
WP3 – Education and Training
Leads: Dr Emma Magavern, Dr Maria Tsakiroglou
Purpose: Upskill stakeholders in pharmacogenomics and regulatory pathways through collaboration with the British Pharmacological Society and development of an educational platform.
WP4 – Health Economics of PGx
Leads: Professor Dyfrig Hughes, Dr Chris Sampson
Purpose: Assess the health, societal, and economic benefits of pharmacogenomics, conduct stakeholder consultations, and develop an economic model framework for NHS implementation.
WP5 – Patient and Public Engagement
Leads: Dr John McDermott, Dr Ramona Moldovan
Purpose: Integrate patient and public voices into regulatory decision-making, focusing on patient information leaflets and direct-to-consumer pharmacogenomic testing.
News & Events
-
New Module Launched on CERSI-PGx Training and Education Platform
Responsive Regulatory Action from Signals in Post-Marketing Surveillance — Toxicity Case Studies This module addresses the significance of post-marketing pharmacogenomic (PGx) surveillance and its role…
-
CERSI-PGx Workshop – 10 September 2026
We would like to extend an invitation to all our CERSI-PGx friends and colleagues to join us at the next CERSI-PGx on-line workshop to be…
-
New CERSI-PGx Guideline published!
We are delighted to announce that the CERSI-PGx has published its latest PGx prescribing guideline. We have made recommendations for the optimisation of clozapine prescribing…
-
PPIE Publication
We are pleased to share the publication of our paper, “Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross-sectional analysis,”…
-
New CERSI-PGx Clinical Guidelines: HLA Genotyping for carbamazepine, oxcarbazepine and eslicarbazepine
We are delighted to share the publication of the second CERSI-PGx guideline on the use of HLA testing to optimise the prescribing of carbamazepine, oxcarbazepine…
-
New CERSI-PGx Clinical Guidelines: Universal CYP2C19 Genotyping for Clopidogrel Prescribing
CERSI-PGx has published comprehensive UK clinical guidelines recommending universal CYP2C19 genotype testing for patients prescribed clopidogrel. Covering stroke, coronary artery disease, and peripheral arterial disease,…